Clinical Trial Update: Nexavar Post-marketing Surveillance for RCC in Japan: Early Access Program

View source ↗

Summary

Sorafenib (Nexavar) underwent post-marketing surveillance for renal cell carcinoma in Japan under an Early Access Program and the program has completed. The upd…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• Nexavar (Sorafenib)

Snippet

Sponsor: Bayer | Conditions: Carcinoma, Renal Cell | Status: COMPLETED